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ACT = activated clotting time; ADP = adenosine diphosphate; AMI = acute myocardial infarction; BAAS = Balloon Angioplasty and Anticoagulation
Study; CAPTURE = c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina; CI = confidence interval; CLASSICS = Clopidogrel/Aspirin
Stent International Cooperative Study; EPIC = Evaluation of c7E3 for the Prevention of Ischemic Complications; EPILOG = Evaluation in PTCA to
Improve Long-term Outcome with abciximab GP IIb/IIIa blockade; EPISTENT = Evaluation of Platelet IIb/IIIa Inhibition in Stenting; ESPRIT =
Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy; ESSENCE = Enoxaparin versus Heparin in Unstable Angina and Non
Q Wave Myocardial Infarction; FANTASTIC = Full Anticoagulation Versus Aspirin and Ticlopidine After Stent Implantation; GP = glycoprotein;
HELVETICA = Hirudin in a European Trial versus Heparin in the Prevention of Restenosis after PTCA; IMPACT = Integrilin to Minimize Platelet
Aggregation and Coronary Thrombosis-II; ISAR = Intracoronary Stenting and Antithrombotic Regimen; LMWH = low molecular weight heparin;
MATTIS = Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting; NICE = National Investigators Collaborating on Enoxaparin; PCI =
percutaneous coronary intervention; REDUCE = Reduction of Restenosis after PTCA, Early Administration of Reviparin in a Double-Blind, Unfrac-
tionated Heparin and Placebo-Controlled Evaluation; RESTORE = Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis;
STARS = Stent Anticoagulation Restenosis Study; TOPPS = Ticlopidine or Plavix Post-Stent; TVR = target vessel reintervention.
Available online http://cvm.controlled-trials.com/content/2/3/129
The acute success rate of percutaneous coronary inter-
vention (PCI) has increased ever since its introduction,
despite a widening scope of indications [1–3]. Neverthe-
less, abrupt vessel closure during or shortly after balloon
angioplasty still occurs in 2–5% of the patients [4–8].
Abrupt closure may result in myocardial infarction
(10–35%) and death (2–5%) despite urgent reinterven-
tion [4–8]. Stents are nowadays placed in more than 50%
of elective interventions, partly because they are very
effective in avoiding vessel closure [7,9]. Stenting,
however, is associated with a unique and devastating
complication, namely (sub)acute thrombosis, which
occurs in 1–4% of the procedures [10,11]. Unfortunately,
the majority of patients who experience this complication
suffer from myocardial infarction and/or die [10,11]. Throm-
bosis plays a major role in acute vessel closure both after
balloon angioplasty and after stenting. This review will
address the value of antiplatelet and anticoagulant therapy
to prevent thrombotic complications after PCI. We will
focus on agents that are routinely available and commonly
used. As the role of thrombosis differs for stented and non-
stented lesions, the therapeutic options during and after
balloon angioplasty and stenting are discussed separately.
In addition, the unique pathophysiology of late thrombotic
closure after intracoronary brachytherapy and the extended
need for antithrombotic therapy will be discussed.
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Balloon angioplasty
Mechanisms of abrupt vessel closure after balloon
angioplasty
Studies using angioscopy [12–14] and post-mortem
observations [15–17] suggest that balloon angioplasty
very often leads to rupture of the obstructing plaque and
to dissection of the vessel wall followed by mural throm-
bus formation. The etiology of abrupt vessel closure is
multifactorial: dissection leading to an occlusive ‘flap’,
spasm, elastic recoil and intramural hematoma may all play
a role. Mural thrombosis is considered an important associ-
ated cause in this process [6,18,19], particularly when the
target lesion has a large lipid core [20] and when mural
thrombosis is already present before intervention [21–24].
Antiplatelet and anticoagulant therapy to prevent
abrupt vessel closure in balloon angioplasty
Aspirin (acetylsalicylic acid)
Aspirin is a dose-dependent inhibitor of platelet cyclo-
oxygenase activity, resulting in a partial inhibition of
platelet activation. A dose of 100 mg aspirin almost com-
pletely suppresses thromboxane A2 synthesis in normal
subjects and in atherosclerotic patients [25]. The onset
of action of aspirin is rapid, showing antiplatelet effects
as soon as 1 hour after oral administration [25]. However,
the appropriate dosing of aspirin is less clear for several
reasons. First of all, the dosage required to inhibit platelet
aggregation varies for each subject [26]. Furthermore,
the effect of aspirin treatment seems to attenuate over
time [27]. This may be overcome by giving a loading dose
of at least 500 mg shortly before angioplasty to all
patients, including those on daily aspirin, to obtain imme-
diate platelet inhibition [28]. Additional reasons to admin-
ister a loading dose are that doses lower than 2 mg/kg
body weight per day may take several days to exert
maximal effect, and that larger doses (>300 mg) reduce
thrombin formation [25,29]. This effect on thrombin for-
mation may be particularly important during PCI, as rup-
tured lesions and damaged vessel walls activate platelets
directly through thrombin. This activation pathway is not
blocked by aspirin [30]. Thrombin plays a pivotal role in
thrombus formation as it converts fibrinogen to fibrin, and
it amplifies its own generation by activating platelets and
the blood coagulation factors V, VIII, and XIII, which then
stabilizes the fibrin clot [31].
The clinical effects of aspirin during balloon angioplasty
have not been studied extensively. Only three randomized
placebo-controlled trials have been conducted [32–34].
Limited numbers of patients were included, and two of
these studies were primarily designed as angiographic
restenosis trials [34,35]. Aspirin nevertheless reduced
the acute complication rate in all three trials (Table 1). In
addition, Mufson et al randomized 495 patients to
80 mg/day aspirin versus 1500 mg/day aspirin and found
no significant difference in the acute complication rate
after balloon angioplasty [35]. In conclusion, aspirin
reduces thrombotic complications during balloon angio-
plasty. However, aspirin is unable to prevent thrombotic
complications completely, even in combination with
heparin. In particular, if the intervention damages the
deeper layers of the vessel wall, the combination of
aspirin and heparin is insufficient [36,37]. Using
angioscopy, thrombosis is detected in more than 50% of
the dilated vessels despite this combined therapy
[14,37,38]. There are at least four reasons why mural
thrombi are resistant to the aspirin–heparin combination.
First, as already described, thrombin is a potent cyclo-
oxygenase independent platelet agonist. The thrombin
receptor on the platelet is not blocked by aspirin [30].
Second, activated platelets bind prothrombin and throm-
bin, shielding them from inactivation by heparin [39,40].
Bound prothrombin generates thrombin about 105 times
more efficiently than the unbound form [31]. Third, throm-
bin also binds to fibrin and to the subendothelial matrix,
where it is shielded from the heparin–antithrombin-III
complex [41–43]. Finally, heparin is antagonized by
platelet factor 4, which is released during aggregation,
and by fibrin II monomers, which are a split product from
fibrin formed to stabilize the thrombus [44,45].
Table 1
The effect of aspirin on acute complications after balloon angioplasty
Reference Drug (mg/day) End points Complications (%)
White et al [32] (n = 333) 650 mg ASA and 225 mg  AMI and/or CABG 5* versus 2* versus 14
dipyridamole, or 750 mg ticlopidine, 
or placebo
Schwartz et al [33] (n = 376) 330 mg ASA and 225 mg  Q-wave AMI 1.6* versus 6.9
dipyridamole, or placebo
Chesebro et al [34] (n = 207) 975 mg ASA and 225 mg  Occlusion, AMI, urgent  11 versus 20
dipyridamole, or placebo reintervention
AMI, acute myocardial infarction; CABG, coronary artery bypass surgery. *P < 0.05 versus placebo.c
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In summary, aspirin pretreatment is essential for patients
undergoing balloon angioplasty. The optimal dosing,
however, is still largely unknown. A high-dose bolus of
aspirin (500 mg) before intervention in addition to a daily
low dose (100 mg/day) seems to be the most efficacious
regimen to reduce platelet activation. Nevertheless, aspirin
is unable to abolish platelet activation totally, suggesting
that additional antithrombotics are necessary during
balloon angioplasty.
Unfractionated heparin
Heparin is a glycosaminoglycan, composed of a heteroge-
neous mixture of molecules of different weights. The anti-
coagulant action of heparin is due to the binding of
one-third of these molecules to antithrombin-III, leading to a
conformational change that markedly increases the ability
to inactivate thrombin [46]. The anticoagulant response to
heparin varies greatly among patients. This may be due to
different concentrations of heparin-binding proteins, and
receptors on endothelial cells, which have to be saturated
before therapeutic plasma levels can be achieved [46].
Natural inhibitors of heparin may, in addition, be released
from the thrombus and are more likely to play a role when
large amounts of thrombus are present [46].
Anticoagulation during PCI is almost universally accom-
plished with unfractionated heparin. A bolus injection of
5000–10,000 IU is commonly used at the start of the PCI,
and a varying amount is added during the procedure. Few
controlled studies have, however, addressed the issue of
optimal dosing or duration of heparin therapy. Several
observational studies [6,47–49], but not all [50], have
associated a low activated clotting time (ACT) with a
higher rate of abrupt vessel closure. Moreover, a retro-
spective analysis suggested a temporal association
between discontinuation of heparin and the occurrence of
abrupt vessel closure [51]. Monitoring of optimal
heparinization and an ACT >300 s therefore seem advis-
able [47]. In contrast, two prospective non-randomized
studies using a single low dose of 2500–5000 IU heparin
[52,53] and two small, randomized trials comparing low-
dose versus high-dose heparin [54,55] suggested that
low-dose heparin is as safe and effective as high-dose
heparin in elective PCI. Without defining an optimal dose,
these studies have introduced a trend towards the use of
lower heparin doses. Recently, however, an analysis com-
bining data from six randomized controlled trials was per-
formed to determine the optimal range of ACT [56]. This
analysis included 6146 patients from studies of novel
adjunctive antithrombotic regimens in which unfraction-
ated heparin constituted the control arm. An ACT of
350–375 s provided the lowest composite event rate at
7 days follow-up. The lowest level of bleeding was
observed in the range of 325–350 s, and it progressively
increased at 350–375 s. An ACT of 350 s therefore
seems to be optimal to prevent ischemic events during
PCI while not increasing bleeding complications [56].
Although heparin is essential during PCI, it should not be
continued after successful coronary intervention. Pro-
longed heparinization does not reduce ischemic complica-
tions, but leads to more bleeding complications, longer
hospital stay and increased costs [57,58]. Small retro-
spective data, on the contrary, suggest that pretreatment
with heparin reduces the risk of complications during PCI
for patients at high risk of coronary thrombus [59–61]. For
these high-risk patients, however, the platelet glycoprotein
(GP) IIb/IIIa receptor blockers have been shown to be
more efficacious (see section ‘Platelet GP IIb/IIIa receptor
blockers’) [62,63].
In summary, unfractionated heparin is effective during
elective PCI, and an ACT of 350 s seems to be optimal to
prevent ischemic events during PCI while not increasing
bleeding complications. Prolonged heparinization after
elective PCI does not reduce complications.
Low molecular weight heparin
Low molecular weight heparins (LMWHs) have a number
of advantages over unfractionated heparin therapy.
LMWHs are fragments of standard heparin molecules with
a more predictable anticoagulant effect requiring less strin-
gent monitoring of anticoagulation. They have a higher ratio
of antifactor Xa:antifactor IIa, they induce thrombocytope-
nia less often, and they are resistant to inactivation by acti-
vated platelets [64]. However, experience with LMWHs in
the setting of coronary intervention is limited. The available
data nevertheless suggest that LMWHs are safe and effec-
tive during PCI. First, the administration of a single intra-
venous bolus of enoxaparin was tested in the open-label
National Investigators Collaborating on Enoxaparin (NICE)-
1 and NICE-4 trials [65]. In NICE-1, 810 patients (up to
85% of who received a stent) were treated with 1 mg/kg
intravenously. In NICE-4, 817 patients (again most of them
stented) received a lower dose of enoxaparin (0.75 mg/kg
intravenously) in combination with abciximab. Preliminary
results showed a low clinical event rate and low bleeding
rate, which suggests that enoxaparin is effective during PCI
without coagulation monitoring [65]. In addition, analysis of
sub-groups from the Enoxaparin versus Heparin in Unsta-
ble Angina and Non Q Wave Myocardial Infarction
(ESSENCE) trial also suggested that enoxaparin is safe
during PCI [66]. Second, the LMWH reviparin was tested
in the Reduction of Restenosis after PTCA, Early Adminis-
tration of Reviparin in a Double-Blind, Unfractionated
Heparin and Placebo-Controlled Evaluation (REDUCE) trial
[67]. A total of 625 patients were randomized to reviparin
initiated as a bolus immediately before PCI and continued
for 24 hours intravenously plus 28 days subcutaneously, or
to unfractionated heparin for 24 hours intravenously. At
30 weeks, the adverse event rate was similar in the two
groups. However, less early complications, primarily the
need for bailout stenting, occurred in the reviparin group
Available online http://cvm.controlled-trials.com/content/2/3/129(3.9% versus 8.2% in the unfractionated heparin group;
P = 0.03) [67]. Third, Collet et al tested a strategy of sub-
cutaneous 1 mg/kg enoxaparin given twice a day for
48 hours followed by angiography and PCI at the treating
physician’s discretion. A total of 451 consecutive patients
with unstable angina or non-Q-wave infarction were
included, of whom 65% underwent angiography and 28%
underwent PCI. Patients were scheduled for catheteriza-
tion within 8 hours of an enoxaparin injection and sheaths
were pulled ³10 hours after enoxaparin injection. Results
showed no increase in major bleeding rate of PCI patients
compared with patients not undergoing catheterization. In
addition, enoxaparin was effective as no abrupt closure or
urgent revascularization occurred after PCI [68].
In summary, LMWHs seem to be safe during PCI,
although the superiority of LMWHs over unfractionated
heparin during PCI remains to be proven.
Direct thrombin inhibitors
The most potent direct antithrombin is hirudin, which
(unlike heparin) forms a 1:1 complex directly with throm-
bin. It is able to inactivate both free thrombin and thrombin
bound to fibrin. In addition, also unlike heparin, there are
no circulating inhibitors of hirudin and it does not bind to
endothelial cells or plasma proteins. The result is that
hirudin achieves a more specific and consistent state of
anticoagulation [69].
In the Hirudin in a European Trial versus Heparin in the Pre-
vention of Restenosis after PTCA (HELVETICA) trial, 1141
unstable patients undergoing angioplasty were randomly
assigned to two regimens of hirudin or to unfractionated
heparin for the duration of 4 days. Although the primary end
point of event-free survival at 7 months was similar in the
three groups, the administration of hirudin was associated
with a significant reduction of early cardiac events (com-
bined relative risk with hirudin, 0.61; 95% confidence inter-
val [CI], 0.41–0.90), while the incidence of bleeding
complications was not increased [70]. In the Hirulog Angio-
plasty Study, 4098 patients undergoing angioplasty for
unstable or post-infarction angina were randomized to either
bivalirudin (Hirulog) or unfractionated heparin for the dura-
tion of 1 day. Bivalirudin did not reduce the primary end
point consisting of any acute complication during hospital-
ization (11.4% versus 12.2% for heparin, P= not signifi-
cant), but it did result in a lower incidence of bleeding (3.8%
versus 9.8%, P< 0.001). Bivalirudin significantly reduced
the primary endpoint in the high-risk subgroup of post-infarc-
tion angina (9.1% versus 14.2%, P= 0.04), again with a
lower incidence of bleeding (3.0% versus 11.1%,
P< 0.001) [71]. A limitation to the use of the direct thrombin
inhibitors is that they are more expensive than heparin.
In summary, the direct thrombin inhibitors are promising
for the prevention of acute complications during PCI.
Platelet GP IIb/IIIa receptor blockers
Because of the relatively weak antiplatelet effects of aspirin,
agonists such as thrombin, collagen, and serotonin can
induce the functional expression of the platelet GP IIb/IIIa
receptor. This receptor cross-links adjacent platelets by
binding fibrinogen and von Willebrand factor. This process
takes place regardless of which metabolic pathway initiated
platelet activation, and the GP IIb/IIIa receptor is therefore
the final common pathway for platelet aggregation. The
best-studied parenteral agents that block the GP IIb/IIIa
receptor include the chimeric c7E3 monoclonal antibody
fragment abciximab, the peptide inhibitor eptifibatide and
the non-peptide mimetic tirofiban. In patients undergoing
balloon angioplasty, most placebo-controlled studies were
performed with the use of abciximab. These studies evalu-
ated the effect on the composite 30-day end point of death,
acute myocardial infarction (AMI) or target vessel reinterven-
tion (TVR) (Table 2). Patients in these studies were addition-
ally treated with aspirin, but variable dosages of
unfractionated heparin and stents were used only for bailout
situations (12% of the patients).
Abciximab: In the Evaluation of c7E3 (abciximab) for the
Prevention of Ischemic Complications (EPIC) study, 2099
high-risk patients (unstable angina, AMI or adverse angio-
graphic characteristics) undergoing balloon angioplasty or
atherectomy were randomly assigned to one of three
groups. These received either placebo bolus plus 12 hours
abciximab infusion, abciximab bolus plus 12 hours placebo
infusion, or abciximab bolus plus 12 hours abciximab infu-
sion. Patients were given full heparin doses (ACT,
300–325 s). There was a significant 4.5% absolute reduc-
tion of the composite 30-day end point in the group on
abciximab bolus plus infusion. In comparison, the abciximab
bolus alone was not effective. The advantages of abciximab
were partly nullified by a doubling of the number of bleeding
complications [72,73]. In the Evaluation in PTCA to Improve
Long-term Outcome with abciximab GP IIb/IIIa blockade
(EPILOG) study, the benefits of abciximab were shown to
extend to patients with low risk. The patients with unstable
angina and electrocardiogram changes or AMI within the
previous 24 hours were excluded. This study was termi-
nated prematurely for efficacy reasons because, after inclu-
sion of 2792 patients, a significant 6.5% absolute reduction
of the 30-day composite end point was noted in the abcix-
imab group. Furthermore, the use of weight-adjusted low-
dose heparin accounted for a lower risk of major bleeding
[74]. The c7E3 Fab Antiplatelet Therapy in Unstable Refrac-
tory Angina (CAPTURE) study evaluated the effect of pre-
treatment with abciximab in patients with refractory unstable
angina who were planned to undergo PCI within 24 hours.
Abciximab was started 18–24 hours before PCI and contin-
ued for 1 hour after the procedure. This study was also dis-
continued prematurely (n = 1266) with a significant 4.5%
absolute reduction of the 30-day composite end point in the
abciximab group.
Current Controlled Trials in Cardiovascular Medicine    June 2001 Vol 2 No 3 ten Berg et alIn the CAPTURE study, unfractionated heparin was not
dosed according to body weight and, again, the number of
bleeding complications doubled [62]. GP IIb/IIIa receptor
blockers are therefore best combined with a weight-
adjusted dose of unfractionated heparin, with an initial
bolus of 70 U/kg and an ACT of approximately 250 s
[74,75]. As already discussed, LMWHs may be superior
to unfractionated heparin, also when combined with GP
IIb/IIIa receptor blockers. There is, as yet, little data on the
safety and efficacy of combining LMWHs with GP IIb/IIIa
receptor blockers during PCI. Preliminary observational
data such as from NICE-4, however, suggest that this
combined antithrombotic regime is promising [65]. With
respect to the duration of abciximab infusion, the lower rel-
ative risk reduction in the CAPTURE study (23%) as com-
pared with that in the EPI trials (35 and 56%) is consistent
with the evidence of subtherapeutic platelet inhibition in a
subgroup of patients 8–12 hours after abciximab infusion
[76]. It therefore seems optimal to continue abciximab
infusion for 12 hours after the intervention.
Integrilin and tirofiban: The small molecules integrilin and
tirofiban were also shown to reduce the risk of PCI,
although less impressively (Table 2). In the Integrilin to Min-
imize Platelet Aggregation and Coronary Thrombosis-II
(IMPACT-II) study, 4010 patients undergoing elective or
urgent interventions were randomly assigned to two differ-
ent doses of  integrilin infusion for 20–24 hours, or to
placebo. There was a non-significant 2.2% absolute reduc-
tion of the 30-day composite primary end point in the best
integrilin group, while bleedings were not increased [77]. In
the Randomized Efficacy Study of Tirofiban for Outcomes
and Restenosis (RESTORE) study, 2139 patients under-
going PCI within 72 hours after an acute coronary syn-
drome were randomly assigned to tirofiban bolus plus
36 hours infusion or to placebo. A significant improvement
in the tirofiban group was noted after 2 days, although after
30 days more than half of this improvement was lost and
finally resulted in a non-significant 1.9% absolute decrease
of the composite end point. Also, tirofiban did not increase
major bleeding [78] (Table 2).
In summary, platelet GP IIb/IIIa receptor blockers
improve the 30-day outcome in almost all subgroups of
patients undergoing PCI. For patients undergoing
balloon angioplasty with provisional stenting, the efficacy
of abciximab is based on the firmest clinical evidence.
With respect to unfractionated heparin, GP IIb/IIIa
receptor blockers are best combined with a weight-
adjusted dose with an initial bolus of 70 U/kg and an
ACT of approximately 250 s. Abciximab should be con-
tinued for 12 hours after intervention.
Oral anticoagulants
Oral anticoagulants inhibit thrombin generation in both the
intrinsic and extrinsic pathways of coagulation. They inter-
fere with the cyclic conversion of vitamin K, which is an
essential cofactor in the carboxylation of blood coagula-
tion factors II, VII, IX and X, and proteins C and S. It takes
several days to obtain a stable level of anticoagulation with
oral anticoagulants.
The effect of oral anticoagulant therapy on acute complica-
tions after PCI had, until recently, not been studied. The
Balloon Angioplasty and Anticoagulation Study (BAAS) ran-
domized 1058 patients undergoing elective angioplasty for
stable or unstable angina to aspirin only or to aspirin plus
oral anticoagulants. Oral anticoagulants were started
1 week prior to the procedure and continued for 6 months.
The target prothrombin time was 2.1–4.8 International Nor-
malized Ratio (INR) during and after the procedure. Oral
anticoagulants significantly improved the 30-day composite
primary end point consisting of death, AMI, TVR and stroke
(3.4% versus 6.4%; relative risk, 0.53; 95% CI, 0.30–0.92).
Available online http://cvm.controlled-trials.com/content/2/3/129
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Table 2
Intravenous glycoprotein IIb/IIIa receptor blockers for patients undergoing percutaneous coronary intervention
Primary end point
Trial Patient category n IIb/IIIa Placebo P value
EPIC [72] AMI, UA or high-risk lesion 2099 8.3 12.8 0.008
EPILOG [74] SA 2792 5.2 11.7 < 0.001
CAPTURE [62] Refractory UA 1265 11.3 15.9 0.01
IMPACT-II [77] AMI, SA,UA 4010 9.2 11.4 0.06
RESTORE [78] UA 2139 10.3 12.2 0.16
EPISTENT [103] AMI, UA, SA and stent eligible 2399 5.3 10.8 < 0.001
See text for details of patient selection, primary end points, and outcome. In the EPIC, EPILOG, CAPTURE and EPISTENT trials, the primary end
point consisted of death, acute myocardial infarction (AMI) or target vessel revascularization (TVR) at 30 days. In the IMPACT-II trial, the need for a
bailout stent also included a primary end point. In the RESTORE trial, not only TVR was included, but any revascularizations. UA, Unstable angina;
SA, stable angina.This positive effect was seen only in those patients in whom
oral anticoagulants were started at least 3 days before the
procedure. Part of this positive effect was offset, however,
by more bleedings in the patients treated with oral anticoag-
ulants. The incidence of major bleedings including false
aneurysms was 3.2% in the oral anticoagulant group versus
1.0% in the patients treated with aspirin alone (relative risk,
3.39; 95% CI, 1.26–9.11) [79].
In summary, oral anticoagulants started before PCI with an
adequate level of anticoagulation during the procedure are
effective in reducing the incidence of acute complications.
Stenting
Mechanism of stent thrombosis
The pathophysiology of stent thrombosis is not fully under-
stood. Stent thrombosis seems to be primarily due to
platelet activation with exposure of the GP IIb/IIIa receptor
for fibrinogen cross-linking and platelet aggregation
[80–82]. However, stent thrombosis is not only a platelet-
dependent process. Vascular wall damage due to stenting
also exposes tissue factor, which subsequently leads to
activation of the extrinsic coagulation cascade with the
generation of thrombin [81].
Antiplatelet and anticoagulant therapy to prevent early
thrombotic complications after stenting
Ticlopidine
Aspirin and ticlopidine interfere with different but comple-
mentary pathways of platelet activation. Ticlopidine selec-
tively inhibits adenosine diphosphate (ADP)-induced
platelet aggregation and ADP-mediated amplification of
other agonists, thereby inhibiting the binding of fibrinogen
to the GP IIb/IIIa receptor. Ticlopidine has a delayed onset
of action with maximal antithrombotic effect after at least
3 days [83].
Four randomized trials (Intracoronary Stenting and
Antithrombotic Regimen [ISAR], Full Anticoagulation
Versus Aspirin and Ticlopidine After Stent Implantation
[FANTASTIC], Stent Anticoagulation Restenosis Study
[STARS], and Multicenter Aspirin and Ticlopidine Trial
after Intracoronary Stenting [MATTIS]) have studied the
combination of aspirin plus 4 weeks of ticlopidine
(250 mg twice daily) versus aspirin plus oral anticoagu-
lants with overlapping unfractionated heparin treatment
in preventing events after stenting [84–87]. All risk cate-
gories were included in these studies. The ISAR study
population consisted of low-risk as well as high-risk
patients, and 24% had an AMI. Randomization took
place once the stent was optimally placed [84]. In the
FANTASTIC trial, randomization was performed before
elective or unplanned stenting. Patients with an AMI
were excluded in this study [85]. In the STARS trial, a
selected group of patients with successful elective stent-
ing for a lesion in a 3–4 mm native coronary artery was
included. Patients in this trial were also assigned to
aspirin alone, which was less effective than the other two
drug regimens [86]. In an earlier randomized trial, aspirin
alone was less effective than aspirin plus ticlopidine for
patients with successful intravascular ultrasound-guided
stent implantation [88]. In the MATTIS trial, randomiza-
tion was performed after bailout stenting or if the result
of stenting was suboptimal [87]. Overall, these studies
show that the combination of aspirin and ticlopidine was
more effective than aspirin plus oral anticoagulants or
aspirin alone (Table 3). However, oral anticoagulants
were started following stent implantation and concomi-
tant unfractionated heparin was used until adequate
levels of anticoagulation were obtained. In this setting,
coumarins might even lead to a transient hypercoagula-
ble state due to rapid suppression of the anticoagulant
activity of protein C relative to the decrease in the level
of factor VII as well as other vitamin K-dependent factors
[89]. Furthermore, unfractionated heparin might not be
effective because it binds to the complex of thrombin
and fibrin, thereby shielding it from inactivation by the
heparin–antithrombin complex [90]. Unfractionated
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Table 3
Aspirin plus ticlopidine versus aspirin plus oral anticoagulants after stenting
Primary end point (%)
Number of  Number of 
Study patients studied patients treated  ASA ticlopidine ASA coumadin ASA alone P value
ISAR [84] 517 626 1.6 6.2 – 0.01
FANTASTIC [85] 473 485 5.7 8.6 – 0.37
STARS [86]  1653 1965 0.5 2.7 3.6 0.001
MATTIS [87]  350 350 5.6 11.0 – 0.07
Hall et al [88] 226 358 0.8 – 3.9 0.1
In the ISAR, STARS, MATTIS and Hall et al studies, the primary end point comprised cardiac death, acute myocardial infarction or repeat target
vessel revascularization at 30 days. In the FANTASTIC study, the composite of death, acute myocardial infarction or stent occlusion at 6 weeks
was the secondary end point and did not include repeat target revascularization.heparin also binds variably to plasma proteins, leading to
unstable levels of anticoagulation, and it has been shown
to activate platelets [90–92]. In contrast, oral anticoagu-
lants in the BAAS were started 1 week before angio-
plasty. In the 35% of the BAAS patients who received a
stent, oral anticoagulants reduced the need for acute
reinterventions and the occurrence of procedure-related
AMI by almost 50% [79]. Stable anticoagulation with
oral anticoagulants might consequently be more effective
than intravenous unfractionated heparin.
Despite its potential advantages, the widespread use of
ticlopidine has been limited by its significant side effect
profile, including diarrhea, nausea, and vomiting, as well as
skin rash. Ticlopidine can also induce neutropenia, bone
marrow aplasia and thrombotic thrombocytopenic
purpura, which may be fatal in some cases [93].
In summary, the combination of aspirin plus ticlopidine is
very effective in preventing thrombotic complications after
stenting. Due to the delayed onset of action and especially
due to its side effect profile, however, ticlopidine has been
replaced by clopidogrel in most centers.
Clopidogrel
Clopidogrel is a new thienopyridine derivative chemically
similar to ticlopidine. Clopidogrel is many times more
potent than ticlopidine and has a more favorable side
effect profile [93,94]. In addition, the onset of action is
more rapid than that of ticlopidine. In one study, significant
inhibition of platelet aggregation appeared 2 hours after
the administration of 400 mg in healthy volunteers and ath-
erosclerotic patients [95].
Several observational studies have recently suggested
that the combination of aspirin plus clopidogrel is as effec-
tive as aspirin plus ticlopidine in preventing stent occlu-
sion [96–99]. The recently reported Clopidogrel/Aspirin
Stent International Cooperative Study (CLASSICS) trial
randomized a selected group of 1020 patients with suc-
cessful stent placement to aspirin plus two dosages of
clopidogrel (75 mg/day orally with or without a 300 mg
loading dose) or to aspirin plus ticlopidine (250 mg twice
daily without a loading dose) for 4 weeks. Clopidogrel and
ticlopidine were first administered within 6 hours after
stent placement. The primary end point consisted of major
peripheral or bleeding complications, neutropenia, throm-
bocytopenia, or early discontinuation of the study drug
due to non-cardiac causes. This primary end point was
reached less often with the use of clopidogrel than with
ticlopidine (9.1% versus 4.6%, P = 0.005). Moreover, the
loading dose of clopidogrel did not lead to more side
effects. The secondary end point, which was cardiac
death, AMI or TVR within 30 days, occurred infrequently
and was comparable between treatment groups (0.9%
with ticlopidine, 1.5 with 75 mg/day clopidogrel only, and
1.2% with clopidogrel 75 mg/day plus a loading dose;
P = not significant for all comparisons) [100].
The second randomized comparison of aspirin plus clopi-
dogrel versus aspirin plus ticlopidine after stenting by
Müller  et al was also designed to study the safety of clopi-
dogrel [101]. Among 793 consecutive patients undergo-
ing an elective or urgent procedure, 700 patients were
randomized after successful stent placement to a 4-week
course of either ticlopidine (500 mg loading dose, then
250 mg/2dd) or clopidogrel (75 mg/day without a loading
dose), in addition to 100 mg aspirin. The 30-day primary
end point, consisting of non-cardiac death, stroke, severe
peripheral vascular or hemorrhagic events, or any adverse
event resulting in discontinuation of study medication,
occurred in 4.5% of the patients in the clopidogrel group
and in 9.6% of the patients in the ticlopidine groups
(P = 0.01). As in CLASSICS, this difference was mainly
due to intolerance to ticlopidine. Cardiac events reflecting
stent thrombosis occurred in 3.1% of the patients treated
with clopidogrel versus 1.7% of the ticlopidine patients
(P = not significant) [101]. Finally, the preliminary data
from the randomized Ticlopidine or Plavix Post-Stent
(TOPPS) trial also showed clopidogrel (loading dose of
300 mg, then 75 mg/day) to be as effective as ticlopidine
(loading dose of 500 mg, then 250 mg twice daily) in a 2-
week regimen after successful stenting in 1016 patients
[102]. In conclusion, clopidogrel seems to be as effective
as ticlopidine and has fewer side effects. One has to bear
in mind, however, that so far the combination of aspirin
and clopidogrel (without a GP IIb/IIIa blocker) has only
been tested in low-risk patients. Whether pretreatment
with thienopyridines is more effective than when it is
started after stenting, is discussed in the section ‘The vul-
nerable period after stenting’.
In summary, clopidogrel is as effective as ticlopidine and
has fewer side effects. A loading dose is essential.
Although the most appropriate duration of clopidogrel
therapy is unknown, at least 2 weeks should be prescribed.
Platelet GP IIb/IIIa receptor blockers
In the Evaluation of Platelet IIb/IIIa Inhibition in Stenting
(EPISTENT) trial, the complementary effects of stenting
and abciximab were studied [103]. A total of 2399
patients scheduled to undergo elective or urgent PCI
were randomly assigned to stent plus placebo, stent plus
abciximab, or balloon angioplasty plus abciximab. The
primary end point consisted of death, AMI, or TVR in the
first 30 days. The primary outcome occurred in 10.8% of
the cases in the stent plus placebo group, in 5.3% in the
stent plus abciximab group (hazard ratio, 0.48; 95% CI,
0.33–0.69) and in 6.9% in the balloon plus abciximab
group (hazard ratio, 0.63; 95% CI, 0.45–0.88). Major
bleeding complications did not increase with the use of
abciximab [103]. Stenting plus abciximab showed superi-
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hority at 6-month and 1-year follow-up. Moreover, abciximab
induced a modest, but significant, reduction of 1-year mor-
tality as compared with placebo (1.0% versus 2.4%;
P = 0.037). This reduction was primarily due to the lower
death rate in patients with diabetes [104].
The second placebo-controlled randomized trial was the
Enhanced Suppression of the Platelet IIb/IIIa Receptor
with Integrilin Therapy (ESPRIT) trial, in which an almost
four times higher dose of eptifibatide than in the
IMPACT-II trial was evaluated. A total of 2064 patients
were included, who were undergoing planned, elective
stenting of native coronaries were included and pre-
treated with aspirin and clopidogrel. Eptifibatide was
administered for 18–24 hours. The primary end point con-
sisted of death, AMI, TVR or bailout GP IIb/IIIa treatment
at 48 hours. The trial was terminated early for reason of
superior efficacy. The results showed a 37% reduction of
the primary end point from 10.5% in the placebo group to
6.6% in the treatment group (P = 0.0015). Major bleeding
was infrequent but higher with eptifibatide (1.3% versus
0.4%, P = 0.027) [105]. In the first direct comparison, the
effect of abciximab was compared with tirofiban in the Do
Tirofiban and Reopro Give Similar Efficacy Trial
(TARGET). This multicenter trial enrolled 4812 patients
who were undergoing stenting. Tirofiban was given at the
dose previously tested in the RESTORE trial and abcix-
imab was given at the dose used in the EPIC trial. At 30
days, the primary composite end point of death, AMI and
urgent TVR occurred in 7.55% of the tirofiban patients
and in 6.01% of the abciximab patients (P = 0.037). Inter-
estingly, in a subgroup analysis, abciximab showed even
more benefit over tirofiban in patients with acute coronary
syndromes, whereas tirofiban showed a trend towards a
better outcome in patients without acute coronary syn-
dromes [106]. In conclusion, GP IIb/IIIa receptor blockers
are very effective in combination with stenting. Abciximab
is more effective than tirofiban but may not be affordable
to all patients. A direct comparison between the less
expensive eptifibatide and abciximab has not been made.
Cost aspects may play a role in decision-making when a
choice between the various GP IIb/IIIA receptor blockers
has to be made.
In summary, platelet GP IIb/IIIa receptor blockers are very
effective in combination with stenting. One has to realize,
however, that this combined treatment is expensive and
may not be affordable to many patients. Nevertheless, GP
IIb/IIIa receptor blockers should be used, at least for high-
risk patients.
The vulnerable period after stenting
Importantly, there appears to be a vulnerable period in the
first days after stenting, which is not fully covered with the
currently used antiplatelet regime [11]. In the FANTASTIC
trial, the acute occlusion rate during the first day after stent-
ing was higher in the antiplatelet group than in the antico-
agulant group (2.4% versus 0.4%, P = 0.06) [85]. Also, in
the ISAR trial, the antiplatelet regimen became superior
only after 3 days of treatment [84]. Furthermore, in the ran-
domized comparison between aspirin plus clopidogrel
versus aspirin plus ticlopidine by Müller et al, six of the nine
cases of stent thrombosis in both treatment groups
occurred before day 2 [101]. These studies consequently
indicate that thienopyridines should be started several days
before intervention. This thesis was also suggested by non-
randomized data [107,108]. In the EPISTENT trial, ticlopi-
dine was started before stenting in 58% of the patients.
Among patients randomized to placebo, the incidence of
the combined end point of death, AMI or urgent revascular-
ization at 30 days was significantly lower for patients who
had received ticlopidine before the procedure, as com-
pared with those who had not (8.9% versus 13.4%,
P = 0.03). Pretreatment with ticlopidine, however, had no
influence on the combined end point at 30 days among
patients randomized to abciximab. Ticlopidine pretreat-
ment, irrespective of the treatment group, was not associ-
ated with an increase in bleeding complications [107].
Additional data suggested that ticlopidine should be
started at least 3 days before stenting to prevent complica-
tions [108]. Also for clopidogrel pretreatment seems to be
effective. In the Clopidogrel in Unstable Angina to Prevent
Recurrent Events (CURE) trial, more than 12,000 patients
presenting with symptoms suggestive of an acute coronary
syndrome were randomized to clopidogrel or placebo. This
trial showed a 20% relative reduction in the composite end
point of death, AMI or stroke after 12 months [109]. Sub-
group analysis showed that there was a consistent benefit
of clopidogrel across all groups, including the group of
patients who had to undergo PCI during follow-up.
In summary, thienopyridines should be started before
stenting. Although the optimal duration of pretreatment is
unknown, starting 2 days before the procedure with a
loading of 300 mg followed by 75 mg/day seems suffi-
cient considering the rapid onset of action of clopidogrel.
Bleeding complications after stenting
In the ISAR, FANTASTIC, MATTIS and STARS studies,
bleeding and groin complications occurred less often in
the patients treated with antiplatelet therapy than in the
patients treated with oral anticoagulation and heparin.
Depending on the definitions used, the incidence of bleed-
ings ranged from 1.2% in ISAR to 13.5% in FANTASTIC
for patients treated with antiplatelet therapy and from
6.2% in STARS to 21% in FANTASTIC in the anticoagu-
lant groups [84–87]. The higher complication rate in the
oral anticoagulant groups may be partly due to the contin-
uation of unfractionated heparin for several days following
stenting while awaiting a stable level of anticoagulation
with oral anticoagulants. In the BAAS, oral anticoagulant
pretreatment obviated the need for post-PCI heparin. The
Current Controlled Trials in Cardiovascular Medicine    June 2001 Vol 2 No 3 ten Berg et alcomplication rate in this study, including false aneurysms,
was again higher in the anticoagulation group (3.2%
versus 1.0%, P = 0.02) but far lower than in the previous
trials [79,84–87].
In the EPISTENT trial, abciximab did not increase the rate
of major bleeding but minor bleedings were increased
(2.9% versus 1.7%) [103]. Data from the ESPRIT trial
show that eptifibatide increases the risk of major and
minor bleedings, but the incidence remains low (major
bleeding, 1.3%) [105].
Patient selection in stent trials
We should realize that most of the aforementioned trials
do not describe the real world, as these studies only
included patients with a successful stent placement, thus
excluding patients in whom a stent could not be placed or
where suboptimal results were obtained. Furthermore, dif-
ferences exist in the definition of the end points that were
used in these trials. For example, both shortcomings
occurred in the STARS trial [86], in which 312 (15.9%) of
the 1965 enrolled patients did not meet the angiographic
criteria for ‘optimal stenting’ and were subsequently ana-
lyzed in the STARS Suboptimal Stent Registry [110]. The
combined 30-day end point comprised death or Q-wave
infarction and occurred in 3% of the registry patients com-
pared with 2.2% of the randomized patients (P = not sig-
nificant). The primary end point did not include
non-Q-wave infarction, which was far more frequent in the
registry patients (8.7% versus 4.2%, P = 0.003). In addi-
tion, the mortality rate was significantly higher in the reg-
istry part of the study (1.1% versus 0.06%, P < 0.009).
Eleven patients in the same group were referred directly
from the cardiac catheterization laboratory for emergency
bypass surgery, and one patient died during stenting.
These 12 patients were excluded from analysis. If these
12 patients had been included, the 30-day event rate in
the registry would have increased to more than 7% [110].
Intracoronary brachytherapy
Restenosis is the main limiting factor of the late success
of balloon angioplasty. Restenosis is due to intimal prolif-
eration and, in particular, due to recoil and remodeling
[111,112]. Stents have reduced the restenosis rate by
eliminating recoil and remodeling [2]. However, stents
enhance intimal proliferation, leading to in-stent restenosis
in about one-fifth of the patients [2]. In-stent restenosis is
very therapy resistant [113]. Intracoronary brachytherapy,
both beta- and gamma-radiation, has recently been proven
to be more effective than balloon angioplasty alone in
treating in-stent restenosis [114–116]. With respect to
thrombotic complications, however, an alarming higher
incidence of late myocardial infarctions was noted after
brachytherapy [114–116]. It is speculated that this higher
late thrombosis rate is due to a delayed re-endothelializa-
tion after radiation. A recent review of randomized and
non-randomized studies reported a late thrombosis rate
after brachytherapy of 9.1%, as compared with 1.2% after
conventional treatment [117]. Further analysis showed
that the combination of brachytherapy and a new stent is
especially prone to late thrombosis [118]. In these initial
trials, the combination of aspirin plus a thienopyridine was
given for 2–8 weeks [114–116]. Data from two registries
(Scripps Coronary Radiation to Inhibit Proliferation Post-
Stenting [SCRIPPS]-III and Washington Radiation for In-
stent restenosis Trial [WRIST]-Plus) as well as preliminary
data from the large randomized BETA-CATH System trial,
however, show low late thrombosis rates when the use of
antiplatelet therapy was extended to 6–12 months
[119–121]. The combined use of aspirin and clopidogrel
should therefore be continued for a minimum of 6 months
after brachytherapy, and for 12 months if a new stent is
implanted [118].
Conclusions
All patients undergoing PCI should be pretreated with
aspirin. A high-dose bolus aspirin several hours before the
procedure in combination with low-dose daily aspirin
seems to be optimal. During PCI, unfractionated heparin
dosed to an ACT of 350 s is advised. LMWHs have
shown promising results, but we have to wait for random-
ized trials before replacing unfractionated heparin during
PCI. The combination of aspirin and heparin is often insuf-
ficient, especially for patients at high risk for ischemic
events. For these patients, additional GP IIb/IIIa receptor
blockers are useful. Oral anticoagulant pretreatment may
be an inexpensive alternative to the GP IIb/IIIa receptor
blockers. The placement of a stent should always be antic-
ipated. Patients should therefore be pretreated with clopi-
dogrel in addition to aspirin. For patients at high risk for
thrombotic complications after stenting, additional GP
IIb/IIIa receptor blockers should be administered.
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